Ishwaria Subbiah: Interesting new study published in the JCO CCI evaluates the utility and privacy of synthetic breast cancer clinical trial data sets

Ishwaria Subbiah shared on LinkedIn:

“Interesting new study published in the American Society of Clinical Oncology (ASCO) journal JCO Clinical Cancer Informatics (JCO CCI) evaluates the utility and privacy of synthetic breast cancer clinical trial data sets but has broader implications for innovation that (inadvertently) perpetuates cancer clinical trials disparities.
– Synthetic data using sequential synthesis methods can act as a proxy for real clinical trial data sets, and simultaneously have low privacy risks.
– This type of generative model can be one way to enable broader sharing of clinical trial data.
– Read the full article here.”

For more details click here.
Source: Ishwaria Subbiah/LinkedIn

Ishwaria Subbiah is the Executive Director for Cancer Care Equity and Professional Wellness at Sarah Cannon Research Institute (SCRI). In this role, Dr. Subbiah focuses on reducing cancer outcomes disparities and diversifying clinical trial participation within SCRI’s combined research network of over more than 1,300 physicians at over 250 locations in 24 states across the US. Dr. Subbiah is a globally recognized expert in geriatric oncology, symptom management, palliative care, and healthcare professional well-being. She previously was an associate professor in the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center. She is the Chair for the ASCO Women in Oncology working group and the ASCO State of Cancer Care in America initiative.